Ulcerative Colitis Treatment Market By Drug Class (Aminosalicylates, Corticosteroids, Immunomodulators, Biologics, JAK Inhibitors, S1P Receptor Modulators, Other Therapies); By Disease Severity (Mild Ulcerative Colitis, Moderate Ulcerative Colitis, Severe Ulcerative Colitis); By Route of Administration (Oral, Injectable, Intravenous, Rectal); By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, Online Pharmacies); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Ulcerative Colitis Treatment Market: IL-23 Launches, Oral Therapies, Biosimilar Competition, and Surgical Care Reshape Demand

The Global Ulcerative Colitis Treatment Market is projected to grow at a CAGR of 5.27%, expanding from USD 9.36 billion in 2025 to USD 13.41 billion by 2032, according to Strategic Market Research.

 

The ulcerative colitis treatment market is moving beyond its historical dependence on aminosalicylates, corticosteroids, and anti-TNF medicines. Revenue growth is increasingly linked to IL-23 biologics, JAK inhibitors, S1P receptor modulators, biosimilars, infusion and specialty-pharmacy services, endoscopic monitoring, laboratory testing, hospital rescue therapy, and colorectal surgery.

 

An estimated 5 million people worldwide live with ulcerative colitis, while approximately 1.25 million patients are located in the United States. Mild-to-moderate disease continues to generate large prescription volumes for mesalamine and related 5-aminosalicylates. Most pharmaceutical value, however, is concentrated in moderate-to-severe disease because patients require higher-priced medicines, repeated safety and disease-activity testing, treatment switching, hospital care, or surgery.

 

Medicines can suppress inflammation and maintain remission, but they do not eliminate ulcerative colitis. Mayo Clinic identifies removal of the colon and rectum as the only treatment that cures the colonic disease. Patients who retain their colon generally require long-term maintenance medication and surveillance, creating recurring healthcare demand rather than a single treatment episode.

 

Lifelong Treatment Creates a Recurring Revenue Base

Ulcerative colitis follows a relapsing and remitting course. Some patients remain controlled on oral or topical 5-aminosalicylates, while others lose response, develop corticosteroid dependence, or progress to advanced medicines and surgery.

Aminosalicylates remain the first treatment step for many patients with mild disease. Oral mesalamine, sulfasalazine, and balsalazide support large recurring prescription volumes, while enemas and suppositories are used when inflammation is concentrated in the rectum or lower colon. Corticosteroids such as prednisone and budesonide are used to control moderate or severe flares but are unsuitable for prolonged maintenance because of systemic complications.

Immunomodulators, including azathioprine and mercaptopurine, continue to serve selected maintenance patients but require regular blood testing because of potential liver, pancreatic, bone-marrow, and infection-related adverse effects. Advanced treatment now spans anti-TNF medicines, vedolizumab, ustekinumab, selective IL-23 inhibitors, JAK inhibitors, and S1P receptor modulators. Physicians can therefore move patients between mechanisms when response declines instead of relying on repeated corticosteroid courses.

Commercial value is determined by the number of patients entering advanced therapy, the duration of remission, switching frequency, adherence, dose intensity, and hospitalisation avoidance. A medicine that maintains steroid-free remission for several years generates substantially more value than one used only for a short induction period.

 

Diagnostic Testing Directly Influences Treatment Selection

Mayo Clinic identifies colonoscopy with tissue biopsy as the central diagnostic procedure for ulcerative colitis. A biopsy is required to confirm the diagnosis and distinguish UC from infections, Crohn’s disease, and other causes of colonic inflammation. Flexible sigmoidoscopy may be used instead of full colonoscopy when the colon is severely inflamed because it examines the rectum and sigmoid colon with less procedural burden.

Blood testing is used to identify anaemia, infection, inflammatory activity, electrolyte abnormalities, and treatment toxicity. Stool studies detect white blood cells or inflammatory proteins and help exclude bacterial, viral, or parasitic infection. Faecal calprotectin testing has become commercially important because it provides a non-invasive measure of intestinal inflammation that can determine whether a patient requires endoscopy, treatment escalation, or continued maintenance.

Severe symptoms may require abdominal X-ray to identify colonic dilation associated with toxic megacolon or perforation. CT of the abdomen or pelvis can detect inflammation, abscesses, and alternative causes of pain. CT enterography and magnetic resonance enterography help exclude inflammation in the small intestine when clinicians need to differentiate ulcerative colitis from Crohn’s disease; MR enterography provides a radiation-free alternative.

Advanced-therapy initiation creates another testing layer. Patients may require tuberculosis and hepatitis screening, complete blood counts, liver-function tests, lipid assessment, pregnancy testing, infection review, and vaccination assessment. JAK inhibitors and S1P modulators require particularly careful risk evaluation, while biologic treatment may involve therapeutic drug monitoring and anti-drug antibody testing when response declines.

Cancer surveillance adds a long-duration endoscopy market. Mayo Clinic recommends colonoscopy every one to two years beginning as early as eight years after diagnosis when disease extends beyond the rectum. The schedule varies according to disease duration, inflammatory burden, and the extent of colonic involvement. A patient diagnosed in early adulthood can therefore undergo repeated colonoscopies, biopsies, pathology reviews, and bowel preparations for several decades.

Endoscopy manufacturers, pathology laboratories, imaging providers, faecal biomarker suppliers, and specialist clinics benefit whenever objective disease assessment is required before starting, continuing, or switching an expensive medicine.

 

Earlier Advanced-Therapy Use Expands the Addressable Market

Updated treatment strategies place less emphasis on prolonged stepwise failure of conventional medicines in moderate-to-severe disease. Physicians increasingly use biologics or targeted oral medicines earlier when 5-ASA therapy is inadequate, corticosteroids cannot be withdrawn, or endoscopy shows persistent inflammation.

Treatment targets have also moved beyond symptom reduction. Gastroenterologists increasingly assess clinical remission, steroid-free remission, endoscopic improvement, endoscopic remission, histological activity, hospitalisation avoidance, and sustained response. This increases the value of products that control both symptoms and visible mucosal inflammation.

Payers are simultaneously restricting access when a new medicine does not show sufficient clinical or economic advantage over lower-cost alternatives. Evidence in biologic-naive and treatment-experienced patients has therefore become central to formulary placement. Manufacturers must demonstrate whether their product works after anti-TNF, vedolizumab, ustekinumab, or JAK inhibitor failure rather than reporting one blended trial result.

 

IL-23 Biologics Build a New Competitive Centre

Selective IL-23 inhibitors have become one of the fastest-developing segments in moderate-to-severe ulcerative colitis. AbbVie’s Skyrizi, Johnson & Johnson’s Tremfya, and Lilly’s Omvoh are competing through remission durability, endoscopic outcomes, dosing convenience, and broader inflammatory bowel disease portfolios.

The FDA approved Skyrizi for ulcerative colitis in June 2024, making it the first selective IL-23 inhibitor approved in the United States for both ulcerative colitis and Crohn’s disease. AbbVie can market the product through an existing specialist, payer, infusion, and patient-support network that also supports Crohn’s disease, psoriasis, and psoriatic arthritis.

Tremfya received U.S. approval in September 2024. In the QUASAR maintenance programme, 50% of patients receiving 200 mg every four weeks and 45% receiving 100 mg every eight weeks achieved clinical remission at week 44, compared with 19% receiving placebo. Endoscopic remission was achieved by 34% and 35% of the two Tremfya groups, respectively, compared with 15% for placebo. These outcomes give Johnson & Johnson evidence for both symptomatic control and visible normalisation of the intestinal lining.

Administration is becoming an equally important purchasing factor. Tremfya initially used intravenous induction followed by subcutaneous maintenance, while later development moved toward a fully subcutaneous treatment pathway. Omvoh uses intravenous induction but now offers a single 200-mg monthly maintenance injection for ulcerative colitis, replacing the previous two-injection regimen. Fewer injections and less infusion-centre use can reduce administration costs and improve patient acceptance.

 

Oral Therapies Compete With Infusion-Led Care

AbbVie’s Rinvoq and Pfizer’s Xeljanz compete within the JAK inhibitor category, while Bristol Myers Squibb’s Zeposia and Pfizer’s Velsipity use S1P receptor modulation. These products avoid infusion appointments and injectable maintenance, shifting spending toward specialty pharmacies and oral-drug monitoring.

Convenience does not remove the need for clinical oversight. JAK inhibitors carry boxed warnings and require assessment of infection, malignancy, thrombosis, and cardiovascular risk. S1P modulators may require cardiovascular evaluation, liver testing, ophthalmic assessment, and infection monitoring. The commercial comparison therefore includes not only acquisition price but also screening costs, safety restrictions, laboratory intensity, and the size of the clinically eligible population.

AbbVie’s 2025 results demonstrate the scale behind the shift from established anti-TNF therapy toward newer mechanisms. Skyrizi generated USD 17.562 billion across all indications and Rinvoq generated USD 8.304 billion, while Humira declined to USD 4.540 billion following biosimilar entry. The figures are not specific to ulcerative colitis, but they show how strongly AbbVie is directing commercial investment toward IL-23 and JAK products.

Pfizer strengthened its oral UC position by acquiring Arena Pharmaceuticals and obtaining etrasimod, now marketed as Velsipity. Companies controlling several mechanisms can retain patients after treatment failure and use one gastroenterology commercial organisation to support multiple therapies.

 

Biosimilars Redirect Competition Toward Net Price

Infliximab and adalimumab biosimilars have changed the role of anti-TNF treatment. Health systems can purchase established therapies at substantially lower negotiated prices, making them reference comparators for newer biologics and oral targeted medicines.

Ustekinumab and vedolizumab are moving into a similar procurement cycle as exclusivity weakens. NHS England estimates that it spends approximately £1.4 billion on biological medicines expected to lose patent protection by 2028 and identifies potential savings of up to £1 billion from timely adoption of best-value biologics. Its framework aims to move clinically suitable new patients rapidly to preferred products and switch appropriate existing patients after biosimilar launch.

Johnson & Johnson’s results illustrate the effect of this transition. Stelara revenue declined 41.3% to USD 6.078 billion in 2025, while Tremfya revenue increased 40.5% to USD 5.155 billion. J&J is replacing an eroding IL-12/23 franchise with a newer selective IL-23 product that has additional patent life and expanding gastrointestinal indications.

Reimbursement agencies are also setting explicit price conditions. Canada’s assessment of Omvoh estimated that a price reduction of approximately 65% would be required to reach a CAD 50,000-per-QALY cost-effectiveness threshold. An estimated reduction of at least 83% was required for its treatment cost to match the least expensive advanced therapy under an equal-efficacy assumption.

The Medicare negotiated price for Stelara took effect in 2026 at USD 4,695 for a 30-day-equivalent supply. Biosimilar tendering, confidential rebates, continuation rules, and negotiated prices increasingly determine realised revenue rather than published list prices alone.

 

Surgery Remains a Large Global Treatment Segment

Historical evidence indicates that approximately 20%–30% of people with ulcerative colitis eventually require bowel surgery. Applied directionally to a global UC population of approximately 5 million, between 1 million and 1.5 million existing patients may undergo surgery or remain at lifetime risk of surgical intervention. This is an addressable-risk population rather than an annual procedure count.

Contemporary short- and medium-term risks are lower than historical lifetime estimates. A systematic review reported pooled colectomy rates of approximately 3% at one year, 5% at five years, and 10% at ten years after diagnosis. Another modern review estimated surgery risk at 7% within five years. Earlier diagnosis, biologics, targeted oral therapies, specialist care, and rescue treatment have reduced surgery for some medically refractory patients, but they have not eliminated procedures for severe disease, dysplasia, cancer, perforation, or uncontrolled bleeding.

The United States has approximately 1.253 million people living with UC. Historical summaries have placed eventual colectomy risk near 30%, although modern cohorts report lower rates. Some healthcare summaries cite 30,000–40,000 annual U.S. IBD-related surgical discharges, but this broader figure includes Crohn’s disease and should not be treated as an annual UC colectomy count. U.S. market models should instead combine diagnosed prevalence, disease severity, hospital admissions, and contemporary procedure rates.

European hospital data show that surgical demand has not declined uniformly. A German analysis covered 522,705 inpatient UC cases between 2008 and 2018. The proportion involving colectomy increased from 0.43% to 0.95%, while proctocolectomy remained relatively stable at approximately 0.93%–1.1%. Minimally invasive surgery increased from 14.5% to 65.6%, and laparoscopic cases had lower complication rates than open procedures. The results support rising demand for laparoscopic instruments, energy devices, stapling products, imaging systems, and trained colorectal teams even as biologic availability expands.

India does not have a centralised national UC surgery registry. Rising diagnosis and referral volumes at major gastroenterology centres are increasing procedures for refractory disease, while laparoscopic and staged approaches are becoming more common. Forecasting should use hospital-level procedure data rather than assigning an unsupported national surgical total.

 

Surgical Care Transfers Spending Into Long-Term Pouch Management

Mayo Clinic identifies proctocolectomy as the principal curative operation. The procedure removes the colon and rectum and is usually combined with ileal pouch-anal anastomosis, commonly called J-pouch surgery. A pouch is constructed from the small intestine and attached to the anus, allowing waste to pass without a permanent external bag.

Patients unsuitable for a J-pouch may receive a permanent end ileostomy. A continent ileostomy, or Kock pouch, creates an internal reservoir emptied through a catheter and one-way valve. Operations may be completed in one, two, or three stages according to disease severity, nutritional status, corticosteroid exposure, emergency presentation, and the safety of immediate pouch construction.

Surgery removes colonic ulcerative colitis but does not end healthcare spending. Patients require ostomy appliances, skin-care products, surgical follow-up, nutritional support, pouchoscopy, antibiotics, continence management, and treatment of pouch complications.

In a cohort of 594 patients undergoing ileal pouch-anal anastomosis, 48% developed pouchitis within two years. Recurrent pouchitis was associated with increased outpatient visits, emergency-department use, and hospital admission. Persistent disease may require antibiotics, biologics, small molecules, biopsy, or further surgery.

 

Pipeline Trials Raise the Standard for Durable Remission

Abivax’s ABTECT programme is evaluating more than 1,200 patients across three pivotal studies of oral obefazimod. Among 580 induction responders entering the Phase 3 maintenance study, clinical remission at week 44 reached 50.8% with 25 mg and 51.3% with 50 mg, compared with 10.4% for placebo. Endoscopic remission reached 41.5% and 47.7%, respectively, compared with 9.9% for placebo. Abivax plans a U.S. regulatory submission in late 2026.

The anti-TL1A category is attracting similarly large investment. In the Phase 2b RELIEVE UCCD study, Teva and Sanofi’s duvakitug achieved clinical remission in 36.2% of lower-dose patients and 47.8% of higher-dose patients at week 14, compared with 20.45% for placebo. Phase 3 trials must now establish durability, safety, endoscopic outcomes, and performance after prior advanced-therapy failure.

Pipeline products face a higher commercial threshold than earlier launches. Strong induction results are insufficient unless treatment also sustains steroid-free remission, controls visible inflammation, works in treatment-experienced patients, and competes economically with biosimilars.

 

Ulcerative Colitis Treatment Market Outlook

Market growth through 2032 will be led by increasing advanced-therapy penetration, selective IL-23 launches, oral JAK and S1P products, subcutaneous maintenance, treatment switching, surveillance colonoscopy, laboratory monitoring, and management of acute severe disease.

5-aminosalicylates will continue to lead prescription volume in mild-to-moderate disease. Biologics and targeted oral medicines will account for the largest value contribution because of higher acquisition costs and prolonged maintenance. Intravenous treatment will sustain hospital and infusion-centre revenue, while self-injected and oral products will shift more spending into specialty and retail pharmacy channels.

Biosimilars will constrain prices for mature biologics and influence the access conditions imposed on newly launched medicines. Companies with several mechanisms, strong clinical evidence, patient-support infrastructure, competitive contracting, and home-administration options can retain patients as they move through successive treatment lines.

Surgery remains a material market rather than a disappearing end point. A global lifetime surgical-risk population of approximately 1 million to 1.5 million patients, continued acute severe admissions, cancer surveillance, staged proctocolectomy, ostomy care, and high pouchitis incidence sustain demand after drug failure.

The strongest products will combine durable steroid-free remission, endoscopic improvement, manageable monitoring, convenient administration, and a net price acceptable to payers. No single mechanism is likely to dominate the market: conventional medicines will retain volume, IL-23 inhibitors and oral therapies will drive value, biosimilars will shape procurement, and colorectal surgery will remain necessary for medically refractory disease and long-term complications.

 

Ulcerative Colitis Treatment Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 9.36 Billion
Revenue Forecast in 2032	USD 13.41 Billion
Overall Growth Rate	CAGR of 5.27% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Drug Class, By Disease Severity, By Route of Administration, By Distribution Channel, By Geography
By Drug Class	Aminosalicylates, Corticosteroids, Immunomodulators, Biologics, JAK Inhibitors, S1P Receptor Modulators, Other Therapies
By Disease Severity	Mild Ulcerative Colitis, Moderate Ulcerative Colitis, Severe Ulcerative Colitis
By Route of Administration	Oral, Injectable, Intravenous, Rectal
By Distribution Channel	Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, Online Pharmacies
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Increasing adoption of IL-23 biologics, expansion of targeted oral therapies, rising biosimilar utilization, growing demand for disease monitoring and surveillance colonoscopy, improved access to advanced inflammatory bowel disease care, and continued need for surgical management in medically refractory cases
Customization Option	Available upon request